المؤلفون: Parker CC; Academic Urology Unit, Royal Marsden Hospital, London, UK; Institute of Cancer Research, London, UK. Electronic address: chris.parker@icr.ac.uk., James ND; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Brawley CD; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Clarke NW; Genito-Urinary Cancer Research Group, Department of Surgery, The Christie Hospital, Manchester, UK; Department of Urology, Salford Royal Hospitals, Manchester, UK., Hoyle AP; Genito-Urinary Cancer Research Group, Department of Surgery, The Christie Hospital, Manchester, UK; Department of Urology, Salford Royal Hospitals, Manchester, UK., Ali A; Genito-Urinary Cancer Research Group, Department of Surgery, The Christie Hospital, Manchester, UK; The FASTMAN/Genito-Urinary Cancer Research Groups, Division of Cancer Sciences, and Belfast-Manchester Movember Centre of Excellence, Manchester Cancer Research Centre, University of Manchester, Manchester, UK., Ritchie AWS; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Attard G; UCL Cancer Institute, UCL, London, UK., Chowdhury S; Department of Medical Oncology, Guy's & St Thomas' NHS Foundation Trust, London, UK., Cross W; Department of Urology, St James University Hospital, Leeds, UK., Dearnaley DP; Academic Urology Unit, Royal Marsden Hospital, London, UK; Institute of Cancer Research, London, UK., Gillessen S; Division of Cancer Sciences, University of Manchester and the Christie, Manchester, UK; Division of Oncology and Haematology, Kantonsspital, St Gallen, Switzerland., Gilson C; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Jones RJ; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK., Langley RE; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Malik ZI; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK., Mason MD; Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK., Matheson D; Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton, UK., Millman R; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Russell JM; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Thalmann GN; Department of Urology, University Hospital, Inselspital, Bern, Switzerland., Amos CL; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Alonzi R; Mount Vernon Cancer Centre, London, UK., Bahl A; Bristol Haematology and Oncology Centre, Bristol, UK., Birtle A; Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK; School of Cancer Sciences, University of Manchester, Manchester, UK., Din O; Department of Clinical Oncology, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Douis H; Department of Radiology, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK., Eswar C; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK., Gale J; Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth, UK., Gannon MR; Department of Health Services Research, London School of Hygiene & Tropical Medicine, London, UK., Jonnada S; Department of Oncology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK., Khaksar S; St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, UK., Lester JF; Velindre Cancer Centre, Cardiff, UK., O'Sullivan JM; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK., Parikh OA; Department of Clinical Oncology, East Lancashire Hospitals NHS Trust, Blackburn, UK., Pedley ID; Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK., Pudney DM; Clinical Oncology, Singleton Hospital, Swansea, UK., Sheehan DJ; Exeter Oncology Centre, Royal Devon & Exeter Hospital, Exeter, UK., Srihari NN; Department of Oncology, Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury, UK., Tran ATH; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Parmar MKB; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK., Sydes MR; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK. Electronic address: mrcctu.stampede-publications@ucl.ac.uk.

مؤلفون مشاركون: Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators

المصدر: Lancet (London, England) [Lancet] 2018 Dec 01; Vol. 392 (10162), pp. 2353-2366. Date of Electronic Publication: 2018 Oct 21.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms/*pathology , Prostatic Neoplasms/*radiotherapy, Aged ; Antineoplastic Agents/therapeutic use ; Disease-Free Survival ; Docetaxel/therapeutic use ; Gonadotropin-Releasing Hormone/agonists ; Gonadotropin-Releasing Hormone/antagonists & inhibitors ; Humans ; Lymph Nodes/pathology ; Male ; Middle Aged ; Neoplasm Metastasis ; Orchiectomy ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/surgery ; Radiotherapy/adverse effects ; Standard of Care ; Survival Analysis ; Treatment Outcome